REVIVE Prospective Registry Cohort Study
The main purpose of this registry is to collect observational, long-term safety and effectiveness data in participants who have received iltamiocel as part of the blinded portion of the REVIVE clinical study.
Has completed the Month 24 visit in the REVIVE study. [+2]
Has received placebo as part of the blinded portion of the REVIVE study. [+2]